GSK Admits Voltaren Marketing Misled Australian Consumers, Now Facing Financial Penalty
Executive Summary
GSK has admitted misleading Australian consumers with the marketing of its Voltaren range by claiming Osteo Gel was specifically formulated for treating osteoarthritis conditions, and was more effective than Emulgel to treat those conditions, when the two products were identically formulated. While a change to Osteo Gel's packaging has since satisfied Australia's Federal Court, GSK is still facing a financial penalty for its earlier conduct.